Marking a decade of IO360°, the IO360º summit brought together leaders from the science and business communities for a comprehensive program focused on data-driven advancements in immuno-oncology.
Click this text to access the full recap
Day One’s opening keynote, Dr Taha Merghoub, Weill Cornell Medicine, outlined the history of IO, looking beyond PD-1 towards future clinical evolution, and potential mechanisms to enhance the potency of IO. Keynote Dr Laura Esserman, University of California San Francisco, presented how she had used neoadjuvant strategies to assess IO candidates, through her I-SPY trial platform. Dr Ira Mellman, Genentech, gave a keynote on combining AI and empirical science; Dr Alex Snyder, Generate Biomedicines, gave a visionary talk how generative AI can directly impact how drugs are developed, and a panel discussion focused on how to use AI to leverage data from the clinic to iterate next-generation drugs. Day One also included the second-annual Women Leaders in IO Luncheon and Panel Discussion on mentoring and mentorships.
Day Two began with an Analyst Keynote from Dr Andrew Baum, Citi, who spoke about what’s next on the IO radar, including an updated list of his top 10 recommendations. Zeitgeist Talk Dr Jason Luke, University of Pittsburgh/UPMC Hillman Cancer Center, traced the last decade of IO to pull lessons on IO biomarkers for target discovery, differentiating mechanisms and IO resistance biology. With patient advocate Cindy Geoghegan, Kelly Spill-Bonito told the story of how an immunotherapy trial saved her life and preserved her ability to have a family. Kalli Dircks, Morgan Stanley, spoke about the biotech markets and IO outlook. Rajiv Kaul, Fidelity Investments, discussed public investing in a difficult IPO market. The day ended with the annual IO360° Debate on the top next-gen approaches to challenges in cancer immunotherapy.
For Day Three, CEO Keynote Dr Patrick Hwu, Moffitt Cancer Center, used his expertise and deep experience in tumor-infiltrating lymphocytes, to discuss his lab’s work and the future of TIL therapy. Keynote Dr Margaret Callahan, University of Connecticut, gave a historical perspective of tumor vaccines and pivoted to the future, where the newest RNA vaccines could find success. Dr Tanya Keenan, Merck, gave a systematic evaluation of TIGIT. Dr Mai-Britt Zocca, IO Biotech, gave an update on immune- modulating cancer vaccines. Dr Rachel Salazar, Bicara Therapeutics, discussed tumor-targeting with a focus on TGFβ. Dr Benoit Rousseau, Memorial Sloan Kettering Cancer Center, closed the program with a dostarlimab data update for MSI-high rectal cancer.
Across the three days, there were panel discussions on how to use AI to leverage data from patients in the clinic to iterate next-gen immunotherapies; leveraging the rise of Chinese biotechs in IO; investment trends in IO; key learnings from manufacturing to help accelerate the process and development of cancer cell-based immunotherapies; synergizing radiopharmaceutical therapy and immunotherapy for optimal cancer treatment outcomes; unlocking the potential of ctDNA for prognostic stratification, tumor evolution insights, and accelerated drug development.
Across multiple tracks, IO360° speakers presented on discovery, preclinical & payload modification; translational science, imaging & biomarkers; IO cell therapy; cell therapy: discovery hypothesis generating data; cell therapy: data from the clinic; and IO and cell therapy clinical developments.
We are pleased to share highlights from IO360° 2024 and also provide recommended media and upcoming events. A big thank you to everyone who participated in this year’s event. Click on the PDF below for a deeper look at the event, speakers and key topics and data.
PDF:
I0360 2024 Recap.pdf
